David J. Flavell FRCPath is a British academic research scientist who specializes in the development of antibody-based treatments for adults and children with various forms of leukaemia and lymphoma.

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article's tone or style may not reflect the encyclopedic tone used on Wikipedia. (January 2011) A major contributor to this article appears to have a close connection with its subject. (January 2011)

Born in Southport, Lancashire, in 1953, he obtained his bachelor's degree in applied Biology from Liverpool in 1975, and his Ph.D. in cancer immunology from Sheffield in 1978. He has held posts at the University of Sheffield (1975–78), Mahidol University, Bangkok, Thailand (1978–79), The University of London, London School of Hygiene and Tropical Medicine (1979–1983)^[1] and the University of Southampton Medical School (1984–2005).^[2] He became a member of The Royal Society of Pathologists in 1997, and later a Fellow of the same Royal Society in 2004.^[3]

With his wife Sopsamorn and two other couples, Flavell started a children's leukaemia research charity, Leukaemia Busters.^[4]

His research is concerned with the development of the next generation of genetically engineered immunotoxins.^[5][6]